Semma Therapeutics is a cell therapy company founded by Doug Melton of Harvard University and financed by ARCH Venture, MPM, and F-Prime. The company was subsequently acquired by Vertex for approximately $1B in late 2019.
In May 2019, Occam placed Mary Kay Fenton as CFO, having years of experience working with fast-growing biotech companies, most recently as EVP and CFO of Achillion Pharmaceuticals. With Fenton in place, Semma was subsequently acquired by Vertex for $1B.
